CVS Health (CVS) 8th Annual Wolfe Research Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
8th Annual Wolfe Research Healthcare Conference summary
9 Nov, 2026Separation rationale
Annual portfolio reviews weigh evolving market, regulatory, competitor and customer dynamics; management sees each business positioned to compete independently and pursue durable long-term growth.
Two years ago, priorities were Aetna margin recovery and retail investment; management now describes the businesses as operating from a position of strength.
Management said expected ongoing dis-synergies are closer to the analyst’s ~$500 million estimate than figures above $1 billion; one-time separation costs will also be incurred.
Both standalone businesses are expected to have solid investment-grade balance sheets; management expects each to grow faster alone than together.
Pharmacy outlook
Retail pharmacy moved from a -5% trajectory three to four years ago to flat at Analyst Day and low-single-digit growth guidance at the earnings call; 2027 is expected to be its third consecutive year of AOI growth.
All pharmacy scripts have moved to a cost-based model after two years of client transitions; management expects reimbursement pressure to stabilize for the most part beyond 2028.
Standalone growth priorities: stabilize reimbursement, grow scripts slightly above market and build adjacent services; further detail is expected over the course of 2027.
Red Oak generic sourcing and the 10+ year wholesaler relationship will continue; Caremark retains brand cost-of-goods capabilities, while CVS Pharmacy remains a major generic purchaser.
Growth opportunities include DTC offerings, weight-loss solutions and scalable clinical and healthcare services across 9,000 local touchpoints.
Remaining healthcare businesses
Medicare Advantage is entering a third year of recovery; management expects continued growth and a return to appropriate margins, while prioritizing margin over growth through the 2028 recovery target.
Management characterized 2027 as a trough year for PBM pressures, with rebate-guarantee mitigation and 340B effects expected to work through by then; it expects a return to its previously indicated growth rate afterward.
Oak Street recovery has advanced, with management expecting positive contributions; PBM pricing is transitioning to a new model in response to FTC, CAA and Department of Labor developments.
The $35 billion deployable-capital figure remains the framework, split between the businesses; planned uses include dividends, share repurchases and appropriate M&A, while maintaining investment-grade positions.
Latest events from CVS Health
- Care delivery expansion and post-deleveraging capital choices shape the forward strategy.CVS
30th Annual Credit Suisse Healthcare Conference - PBM cost controls, health plan growth and integrated care underpin the outlook.CVS
The 2016 Morgan Stanley Global Healthcare Conference - Integrated pharmacy scale supported growth and more than $5B in planned 2016 shareholder returns.CVS
The UBS 2016 Global Healthcare Conference - Integrated pharmacy and clinical programs aim to improve outcomes and reduce care costs.CVS
UBS Global Healthcare Conference 2017 - Signify bolsters in-home care and value-based strategy amid stable utilization.CVS
Morgan Stanley 20th Annual Global Healthcare Conference - Aetna integration targets >$750M in 2020 synergies and broader medical-cost savings.CVS
JP Morgan 37th Annual Healthcare conference - Cost savings and payer partnerships support long-term growth and shareholder returns.CVS
Investor Day 2016 - A $77B Aetna deal targets integrated care and $750M in year-two synergies.CVS
M&A announcement - FY18 operating profit growth guided to 1%–4%, tempered by PBM and deal-related headwinds.CVS
Guidance